Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Aug;46(8):983-990.
doi: 10.1007/s00270-023-03476-0. Epub 2023 Jun 13.

Comparison of Clinical Performance Between Two Types of Symmetric-Tip Hemodialysis Catheters: A Single-Centre, Randomized Trial

Affiliations
Randomized Controlled Trial

Comparison of Clinical Performance Between Two Types of Symmetric-Tip Hemodialysis Catheters: A Single-Centre, Randomized Trial

Pauline Braet et al. Cardiovasc Intervent Radiol. 2023 Aug.

Abstract

Purpose: To compare the clinical performance of a newly designed, symmetric-tip Arrow-Clark™ VectorFlow® tunnelled haemodialysis catheter, with a Glidepath™, symmetric-tip tunnelled haemodialysis catheter.

Material and methods: From November 2018 to October 2020, patients with End-Stage Renal Disease requiring a de novo tunnelled catheter for hemodialysis, were randomized to Vectorflow® (n = 50) or to Glidepath™ catheter (n = 48). The primary outcome was catheter patency at one year following catheter insertion. Catheter failure was defined as the removal of the catheter due to infectious complications, or low blood flow rate by intraluminal thrombosis or fibrin sheath occlusion. Secondary outcomes were blood flow rate, fractional urea clearance and urea reduction ratio during dialysis.

Results: Demographic characteristics were not different between the two groups. At three months and on the one-year endpoint the patency rates with the Vectorflow® catheter were 95.83% and 83.33% respectively, compared to 93.02% at both endpoints with the Glidepath™ catheter (P = 0.27). Catheter failure to infectious complications or low blood flow rate was similar in both groups. Catheter blood flow rate reached the threshold of 300 ml/min at all time points for both catheters. All patients had a high mean fractional urea clearance (1.6-1.7).

Conclusions: The catheter patency rate was not significantly different in patients with a VectorFlow® or a Glidepath™ catheter. Both catheters presented satisfactory dialysis adequacy over one year.

Keywords: Complication; Dialysis; Randomized trial; Tunnelled catheter.

PubMed Disclaimer

Comment in

References

    1. Chan CT, et al. Dialysis initiation, modality choice, access, and prescription: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2019;96:37–47. - DOI - PubMed
    1. Heaf J. Current trends in European renal epidemiology. Clin Kidney J. 2017;10(2):149–53. - DOI - PubMed - PMC
    1. Lok CE, Huber TS, Lee T, et al. KDOQI vascular access guideline work group. KDOQI clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis. 2020;75(suppl 4):S1–164. - DOI - PubMed
    1. Allon M. Vascular access for hemodialysis patients: new data should guide decision-making. Clin J Am Soc Nephrol. 2019;14:954–61. - DOI - PubMed - PMC
    1. Silverstein DM, et al. Clinical and regulatory considerations for central venous catheters for hemodialysis. Clin J Am Soc Nephrol. 2018;13:1924–2932. - DOI - PubMed - PMC

Publication types

LinkOut - more resources